BiotechTube

TBI-1501

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lymphoblastic Leukemia, Acute Adult

Conditions

Lymphoblastic Leukemia, Acute Adult

Trial Timeline

Jun 1, 2017 → Mar 31, 2035

NCT ID
NCT03155191

About TBI-1501

TBI-1501 is a phase 1/2 stage product being developed by Takara Bio for Lymphoblastic Leukemia, Acute Adult. The current trial status is active. This product is registered under clinical trial identifier NCT03155191. Target conditions include Lymphoblastic Leukemia, Acute Adult.

What happened to similar drugs?

2 of 13 similar drugs in Lymphoblastic Leukemia, Acute Adult were approved

Approved (2) Terminated (3) Active (9)
🔄CTL019NovartisPhase 3
❌Tisagenlecleucel + Blinatumomab + InotuzumabNovartisPhase 3
🔄CTL019NovartisPhase 3
🔄Blinatumomab + DexamthasoneAmgenPhase 3
🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3
🔄Blinatumomab + Dexamethasone + Vincrisitne + Daunorubicin + Methotrexate + Ifosfamide + PEG-asparaginase + Erwinia-asparaginaseAmgenPhase 3
🔄Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses + Inotuzumab Ozogamicin+Standard Maintenance Therapy + Imatinib + 6-tioguanine+Standard Maintenance Therapy + BlinatumomabAmgenPhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03155191Phase 1/2Active

Competing Products

20 competing products in Lymphoblastic Leukemia, Acute Adult

See all competitors
ProductCompanyStageHype Score
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
VCL-CB01Astellas PharmaPhase 2
35
SHP674Kyowa KirinPhase 2
35
LY3039478 + Dexamethasone + PlaceboEli LillyPhase 1/2
32
Venetoclax + Navitoclax + Dexamethasone + Vincristine + Calaspargase Pegol + Dasatinib + Cytarabine + Blinatumomab + Methotrexate + Mercaptopurine + Cyclophosphamide + Etoposide + Leucovorin + Intrathecal Triples + Pegaspargase + Erwinia asparaginaseAbbViePhase 1/2
36
ABT-348 + ABT-348 + ABT-348 and azacitidine + ABT-348AbbViePhase 1
29
Dexamethasone + Vincristine + Daunorubicin + Calaspargase pegol + Dasatinib + Venetoclax + Bortezomib + Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) + Cyclophosphamide + Cytarabine + Mercaptopurine + Nelarabine + Methotrexate + ThioguanineAbbViePhase 2
42
Navitoclax + Chemotherapy + VenetoclaxAbbViePhase 1
29
Venetoclax + Dexamethasone + Inotuzumab OzogamicinAbbViePhase 1
33
Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax + BlinatumomabAbbViePhase 1
36
Capivasertib + Venetoclax + Intrathecal chemotherapyAbbViePhase 1/2
39
Selumetinib + DexamethasoneAstraZenecaPhase 1/2
24
AZD3632 + PosaconazoleAstraZenecaPhase 1/2
39
AZD0486AstraZenecaPhase 1/2
39
blinatumomab + pembrolizumabMerckPhase 1/2
32
Zilovertamab vedotinMerckPhase 1/2
39
MK0752, (Notch Inhibitor)MerckPhase 1
21
Standard chemotherapy + ImatinibNovartisPhase 2
35
CTL019NovartisPhase 3
40
Ribociclib + Dexamethasone + EverolimusNovartisPhase 1
33